NephroDI Therapeutics Analysis: $4M Raised
What is NephroDI Therapeutics?
NephroDI Therapeutics is focused on developing an oral drug for nephrogenic diabetes insipidus (NDI) in children, a rare genetic condition. The company aims to address the challenges faced by patients who produce excessive urine due to kidney concentration issues. Their research includes a novel series of AMPK as a potential therapy for NDI.
Location
2200 32nd Ave W, Seattle, Washington 98199, United States
Employees
1-10
Founded
2017
Funding Status
Series A
Product Features & Capabilities
- Oral drug for nephrogenic diabetes insipidus
- Research on AMPK therapy
Use Cases
Treat children with nephrogenic diabetes insipidus; Address severe dehydration in NDI patients; Develop therapies for congenital NDI; Research genetic mutations affecting vasopressin receptors; Collaborate with strategic partners for drug development
Other Considerations
Announced leadership appointments including Dr. Jeff Sands as Chief Medical Officer; Entered agreement with MSRD and Otsuka for NDI treatment development
See something that needs updating? Suggest edits to this profile.